TISIDB

Summary
Symbol	SYCP1
Name	synaptonemal complex protein 1
Aliases	HOM-TES-14; CT8; cancer/testis antigen 8; SCP-1
Chromosomal Location	1p13-p12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Nucleus Chromosome Chromosome, centromere Note=In tripartite segments of synaptonemal complexes, between lateral elements in the nucleus. Its N-terminus is found towards the center of the synaptonemal complex while the C-terminus extends well into the lateral domain of the synaptonemal complex (By similarity). Only rarely detected at centromeres during leptotene and zygotene. Detected at centromeres during mid-diplotene, when it is no longer present along chromosome arms. No longer detected at centromeres at later stages of meiosis (By similarity).
Domain	PF05483 Synaptonemal complex protein 1 (SCP-1)
Function	Major component of the transverse filaments of synaptonemal complexes (SCS), formed between homologous chromosomes during meiotic prophase. Required for normal assembly of the central element of the synaptonemal complexes. Required for normal centromere pairing during meiosis. Required for normal meiotic chromosome synapsis during oocyte and spermatocyte development and for normal male and female fertility.

> Gene Ontology [ TOP ]
Biological Process	GO:0000711 meiotic DNA repair synthesis GO:0000731 DNA synthesis involved in DNA repair GO:0006310 DNA recombination GO:0006323 DNA packaging GO:0006997 nucleus organization GO:0007059 chromosome segregation GO:0007126 meiotic nuclear division GO:0007127 meiosis I GO:0007129 synapsis GO:0007130 synaptonemal complex assembly GO:0007131 reciprocal meiotic recombination GO:0007281 germ cell development GO:0007283 spermatogenesis GO:0007286 spermatid development GO:0007289 spermatid nucleus differentiation GO:0022412 cellular process involved in reproduction in multicellular organism GO:0035092 sperm chromatin condensation GO:0035825 reciprocal DNA recombination GO:0045132 meiotic chromosome segregation GO:0045143 homologous chromosome segregation GO:0048232 male gamete generation GO:0048515 spermatid differentiation GO:0051026 chiasma assembly GO:0051321 meiotic cell cycle GO:0051878 lateral element assembly GO:0070192 chromosome organization involved in meiotic cell cycle GO:0070193 synaptonemal complex organization GO:0071103 DNA conformation change GO:0071897 DNA biosynthetic process GO:0098813 nuclear chromosome segregation GO:1903046 meiotic cell cycle process
Molecular Function	-
Cellular Component	GO:0000775 chromosome, centromeric region GO:0000793 condensed chromosome GO:0000794 condensed nuclear chromosome GO:0000795 synaptonemal complex GO:0000801 central element GO:0000802 transverse filament GO:0001673 male germ cell nucleus GO:0043073 germ cell nucleus GO:0044454 nuclear chromosome part GO:0098687 chromosomal region

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	R-HSA-1640170: Cell Cycle R-HSA-1500620: Meiosis R-HSA-1221632: Meiotic synapsis

Summary
Symbol	SYCP1
Name	synaptonemal complex protein 1
Aliases	HOM-TES-14; CT8; cancer/testis antigen 8; SCP-1
Chromosomal Location	1p13-p12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between SYCP1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining

[ TOP ]

Literatures describing the relation between SYCP1 and anti-tumor immunity in human cancer.

PMID	Cancer type	Relation to immunity	Evidence sentences
16432832	Pancreatic carcinoma	Promote immunity	Serological immune response to cancer testis antigens in patients with pancreatic cancer. In conclusion, antibody response to cancer testis antigen SCP-1 is found in a proportion of pancreatic carcinoma patients.

Summary
Symbol	SYCP1
Name	synaptonemal complex protein 1
Aliases	HOM-TES-14; CT8; cancer/testis antigen 8; SCP-1
Chromosomal Location	1p13-p12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of SYCP1 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	SYCP1
Name	synaptonemal complex protein 1
Aliases	HOM-TES-14; CT8; cancer/testis antigen 8; SCP-1
Chromosomal Location	1p13-p12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of SYCP1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0	1
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0	1
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0	1
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-0.438	0.536
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.011	0.994
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	-0.989	0.497
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0	1
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0	1
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0	1
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0	1
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0	1
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.252	0.133

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of SYCP1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	7.1	0	7.1	0.452
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	10	0	10	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	22.2	15.1	7.1	0.387
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	7.1	-7.1	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	22.2	16.9	5.3	0.563
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	28.6	11.8	16.8	0.257
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	25	16.7	8.3	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	30.8	9.1	21.7	0.327
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	13.2	3.7	9.5	0.388
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	13.6	7.7	5.9	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	12.5	0	12.5	0.485
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	SYCP1
Name	synaptonemal complex protein 1
Aliases	HOM-TES-14; CT8; cancer/testis antigen 8; SCP-1
Chromosomal Location	1p13-p12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of SYCP1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	SYCP1
Name	synaptonemal complex protein 1
Aliases	HOM-TES-14; CT8; cancer/testis antigen 8; SCP-1
Chromosomal Location	1p13-p12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of SYCP1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by SYCP1. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	SYCP1
Name	synaptonemal complex protein 1
Aliases	HOM-TES-14; CT8; cancer/testis antigen 8; SCP-1
Chromosomal Location	1p13-p12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of SYCP1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	SYCP1
Name	synaptonemal complex protein 1
Aliases	HOM-TES-14; CT8; cancer/testis antigen 8; SCP-1
Chromosomal Location	1p13-p12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of SYCP1 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	SYCP1
Name	synaptonemal complex protein 1
Aliases	HOM-TES-14; CT8; cancer/testis antigen 8; SCP-1
Chromosomal Location	1p13-p12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between SYCP1 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	SYCP1
Name	synaptonemal complex protein 1
Aliases	HOM-TES-14; CT8; cancer/testis antigen 8; SCP-1
Chromosomal Location	1p13-p12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting SYCP1 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse SYCP1